Edition:
India

Sucampo Pharmaceuticals Inc (SCMP.OQ)

SCMP.OQ on NASDAQ Stock Exchange Global Market

10.35USD
20 Nov 2017
Change (% chg)

-- (--)
Prev Close
$10.35
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
111,048
52-wk High
$17.50
52-wk Low
$9.30

Latest Key Developments (Source: Significant Developments)

Sucampo reports Q3 GAAP earnings per share $0.19
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Sucampo Pharmaceuticals Inc :Sucampo reports third quarter 2017 financial results.Q3 GAAP earnings per share $0.19.Q3 revenue $61.3 million versus I/B/E/S view $58 million.Q3 earnings per share view $0.25 -- Thomson Reuters I/B/E/S.Sees FY 2017 adjusted earnings per share $1.10 to $1.15.Q3 adjusted earnings per share $0.27.Sucampo Pharmaceuticals Inc - For FY17 ‍sucampo now expects total revenue of $250.0 million to $255.0 million​.Q3 earnings per share view $0.25, revenue view $58.0 million -- Thomson Reuters I/B/E/S.Sucampo Pharmaceuticals Inc - Sees FY 2017 ‍free cash flow of $99.0 million to $104.0 million​.Sucampo Pharmaceuticals - ‍Increases 2017 guidance for all key financial metrics based on "stronger than expected" sales of Amitiza in U.S. & Japan.FY2017 earnings per share view $1.01, revenue view $234.5 million -- Thomson Reuters I/B/E/S.  Full Article

Sucampo reports Q2 GAAP loss per share $0.02
Wednesday, 3 Aug 2016 

Sucampo Pharmaceuticals Inc : Q2 GAAP loss per share $0.02 . Q2 adjusted earnings per share $0.23 . Q2 earnings per share view $0.22 -- Thomson Reuters I/B/E/S . Q2 revenue $52 million versus I/B/E/S view $48.6 million . Sees FY 2016 adjusted earnings per share $0.97 to $1.07 . Sees FY 2016 revenue $195 million to $205 million .FY2016 earnings per share view $1.01, revenue view $203.6 million -- Thomson Reuters I/B/E/S.  Full Article

Sucampo Pharmaceuticals Inc reports top-line data from phase 2a study of cobiprostone
Tuesday, 19 Apr 2016 

Sucampo Pharmaceuticals Inc:Reports top-line data from phase 2a study of cobiprostone in patients with PPI-refractory non-erosive reflux disease and symptomatic gastroesophageal reflux disease.Says trial did not meet its primary endpoints.Says intends to discontinue development of cobiprostone for PPI-refractory NERD/sGERD.  Full Article

Sucampo Pharmaceuticals Inc reiterates FY 2016 guidance
Tuesday, 8 Mar 2016 

Sucampo Pharmaceuticals Inc:Reiterated its earnings guidance for FY 2016.Expects total revenue of $195.0 million to $205.0 million, adjusted net income of $45.0 million to $50.0 million, adjusted EPS of $0.97 to $1.07, and adjusted EBITDA of $100.0 million to $105.0 million.Says adjusted net income guidance excludes amortization of acquired intangibles of about $17.6 million and amortization of the remaining inventory step-up costs of about $8.9 million.  Full Article

Sucampo Pharmaceuticals Inc enters into exclusive collaboration deal with cancer prevention pharmaceuticals
Monday, 11 Jan 2016 

Sucampo Pharmaceuticals Inc:Press release - Sucampo enters into exclusive option and collaboration agreement with cancer prevention pharmaceuticals for development of late-stage cpp-1x/sulindac combination for familial adenomatous polyposis.Says phase 3 study expected to be complete in 2018.Says under the terms of the agreement, Sucampo will invest $5.0 million in cpp in the form of a convertible note.Says in addition, Sucampo will pay cpp an option fee of up to $7.5 million, payable in two tranches.Says under terms of the license, Sucampo and cpp would share equally in profits from the sale of approved products.Sucampo pharmaceuticals-co would acquire an exclusive license to product and would be obligated to pay cpp an aggregate of $190 million.  Full Article

Sucampo Pharmaceuticals Inc confirms FY 2016 guidance
Thursday, 7 Jan 2016 

Sucampo Pharmaceuticals Inc:Confirms its previous guidance for FY 2016 of total revenue of $195.0 million to $205.0 million, adjusted net income of $45.0 million to $50.0 million, adjusted EPS of $0.97 to $1.07, and adjusted EBITDA of $100.0 million to $105.0 million.Says adjusted net income guidance excludes amortization of acquired intangibles of about $17.6 million and amortization of the remaining inventory step-up costs of about $8.9 million.  Full Article

Sucampo Pharmaceuticals Inc CEO Peter Greenleaf appointed board chairman
Wednesday, 16 Dec 2015 

Sucampo Pharmaceuticals Inc:Says CEO Peter Greenleaf appointed board chairman.Peter Greenleaf succeeds Dan Getman.  Full Article